Format

Send to

Choose Destination
Immunotherapy. 2018 Oct;10(14):1265-1284. doi: 10.2217/imt-2017-0168.

Harnessing immune checkpoints for cancer therapy.

Author information

1
Section of Clinical Immunology, Allergy & Rheumatology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
2
Eutilex Institute for Biomedical Research, Suite #1401 Daeryung Technotown 17, Gasan digital 1-ro 25, Geumcheon-gu, Seoul Korea.

Abstract

Immunomodulatory antibodies that directly trigger and reawaken suppressed T-cell effector function are termed 'checkpoint inhibitors'. CTLA-4 and PD-1/PD-L1 molecules are the most studied inhibitory immune check points against cancer and because of this therapeutic property have entered the clinic for treating a variety of tumor types. The results so far demonstrate a positive impact on cancer remission. Preclinical studies have demonstrated that targeting a number of other T-cell surface molecules including both positive and negative immune regulators, also possesses strong antitumor activity. Some of these molecules have already entered clinical trials. In this report, we briefly highlight the status of these immune checkpoint inhibitors and discuss their side effects and future directions for their use.

KEYWORDS:

T cells; cancer; immune checkpoint

PMID:
30326786
DOI:
10.2217/imt-2017-0168

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center